Reduction of ureteral stent encrustation by modulating the urine pH and inhibiting the crystal film with a new oral composition: a multicenter, placebo controlled, double blind, randomized clinical trial

CURRENT STATUS: UNDER REVIEW

Carlos Torrecilla
Hospital Universitari de Bellvitge

Jaime Fernández-Concha
Hospital Universitari de Bellvitge

José R. Cansino
Hospital Universitario La Paz

Juan A. Mainez
Hospital Universitario La Paz

José H. Amón
Hospital Universitario Rio Hortega

Simbad Costas
Hospital General Mateu Orfila

Oriol Angerri
Fundacio Puigvert

Esteban Emiliani
Fundacio Puigvert

Miguel Arrabal Martín
Hospital Universitario San Cecilio

Miguel Arrabal Polo
Hospital Universitario San Cecilio

Ana García
Hospital Universitario de Valme
Manuel C. Reina  
Hospital Universitario de Valme

Juan F. Sánchez  
Hospital Alvaro Cunqueiro

Alberto Budía  
Hospital Universitari i Politecnic La Fe

Daniel Pérez-Fentes  
Hospital Clínico Universitario de Santiago de Compostela

Félix Grases  
Universidad de las Islas Baleares

Corresponding Author  
fgrases@uib.es

Antonia Costa-Bauzá  
Universitat de les Illes Balears

Jordi Cuñé  
Devicare SL

DOI:  
10.21203/rs.2.22208/v1

SUBJECT AREAS  
Urology & Nephrology

KEYWORDS  
double J stent, encrustation, nutraceutical, L-methionine, phytin, pH
Abstract
Background: Encrustation of ureteral double J stents is a common complication that may affect its removal. The aim of the proposed study is to evaluate the efficacy and safety of a new oral composition to prevent double J stent encrustation in indwelling times up to 8 weeks.

Methods: A double-blinded, multicenter, placebo-controlled trial was conducted with 105 patients with indwelling double J stents enrolled across 9 public hospitals in Spain. The patients were randomly assigned (1:1) into intervention or placebo groups for 3 to 8 weeks and both groups self-monitored daily their morning urine pH levels. The primary outcome of analysis was the degree of stent ends encrustation, defined by a 4-point score (0 – none; 3 – global encrustation) using macroscopic and electron microscopy analysis of crystals, after 3 to 8-w indwelling period. Score was exponentially transformed according to calcium levels. Secondary endpoints included urine pH decrease, stent removal, and incidence of adverse events.

Results: The intervention group benefits from a lower global encrustation rate of stent ends than placebo group (1% vs 8.2%; p < 0.018). Mean encrustation score was 85.12 (274.5) in the intervention group and 18.91 (102.27) in the placebo group (p < 0.025). Considering the secondary end points, treated patients reported greater urine pH decreases (p = 0.002). No differences in the incidence of adverse events were identified between the groups.

Conclusions: Our data suggest that the use of this new oral composition is beneficial in the context of ureteral double J indwelling by decreasing mean, as well as global encrustation.

Trial registration: This trial was registered at www.clinicaltrials.gov under the name “Combined Use of a Medical Device and a Dietary Complement in Patient Urinary pH Control in Patients With an Implanted Double J Stent” with date 2 nd November 2017, code NCT03343275, and URL: https://clinicaltrials.gov/ct2/show/record/NCT03343275?term=NCT03343275&draw=2&rank=1

Keywords: double J stent; encrustation; nutraceutical; L-methionine; phytin; pH.

Background
Double-J ureteral stents(1) are one of the most common indwelling ureteral devices used for treatment of obstructive uropathy, postoperative of ureteropyelic stenosis and renal
transplantation(2,3). Their effectiveness for renal collecting system drainage has been proven and their characteristic design, with both renal and vesical J-shaped curl ends, prevents stent migration(1). However, double J ureteral stents have also been related to patient discomfort, pain, urinary tract infection and encrustation(4,5).

The management of encrusted ureteral stents represent a challenging surgical condition for the practicing urologist, being the forgotten the most extreme case(6,7). The challenges result from the potential need for multiple surgical interventions(7). A prolonged indwell time of stents, as well as a history of nephrolithiasis and urinary infections may result in encrustation of ureteral stents, and will lead to the use of endourological techniques, extracorporeal lithotripsy or open surgery to resolve these conditions(8).

Film-formation is a multistep process that seems to be involved in the occurrence of encrustations(9,10) which may lead to stent obstruction or stent removal complications. Shortly after the stent insertion, different organic molecules adhere to its surface forming a multi-layered complex protein structure (conditioning film). Until now, the presence of bacteria attached to the stent surface was considered essential for the formation of struvite and hydroxyapatite crystals(4,11). Nonetheless, recent studies have demonstrated that the presence of bacteria is not compulsory and conditioning film, together with urine pH, might play a bigger role in Ca and Mg phosphate precipitates forming hydroxyapatite and brushite crystals, which result in stent encrustation. In addition to this mechanism, other factors such as urine composition and flow dynamics are also involved(12). In this regard, urinary pH plays an important role and several studies have shown that higher urine pH values are found in blocker patients (those in which stent obstruction is observed) compared to non-blocker ones(10,13,14). Thus, stent encrustation could be minimized if urine composition is altered by reducing the urine alkalisation and increasing the urine excretion of crystallization inhibitors.

The oral composition studied contains both urine acidifier and crystallization inhibitors, such us L-methionine (an essential amino acid recommended by the EAU Guidelines on Urolithiasis with acidifier properties for the treatment of infectious stones) and phytin (a phytate salt with demonstrated
inhibitory properties of calcium stones) as active components. L-methionine directly reduces/acidifies urine pH(15,16), whereas crystallization inhibitors(17) decrease the risk of renal stone formation(18,19).

On the other hand, the pH meter is a medical device designed for urine pH self-monitoring, enabling patients to easily control urine pH on their own and consequently, adjusting their treatment according to their physician’s advice. This device has been validated with patients(20,21) and its applicability may be extended to other urological pathologies where urinary pH plays an important role, such as acid-base imbalance diseases, urinary tract infections, cystitis, painful bladder syndrome or stent encrustation(22–24).

The main goal of this study was to assess the potential in preventing double-J stent encrustation of a new oral composition in a study with indwelling times between 3 and 8 weeks, as well its efficacy and safety. Secondary objectives included urine pH decrease, stent removal, incidence of adverse events, patient’s compliance and physician’s and patient’s satisfaction. The results observed reveal a significant decrease in global encrustation in the intervention group even in the short period of time applied in this study. We also observe a higher urinary pH decrease in the experimental group, being lower urinary pH a protective factor against encrustation. Altogether these promising data pave the way to further investigations for the use of the oral composition in longer indwelling times of double J stents.

Methods
Study design
A prospective, parallel, double-blinded, randomized and placebo-controlled trial was conducted between 9th January 2018 and 9th July 2018 at 9 public hospitals in Spain, in accordance with the Declaration of Helsinki, ethical standards, current legislation and GCPs. The study was approved by local Ethics Committees, and informed consent was obtained from all patients prior to their enrolment in the study. This study adhere to CONSORT guidelines.

Subjects
The recruitment period was from January to July 2018. Inclusion criteria comprised patients aged 18 and older, capable of daily self-monitor their urine pH, who were willing to participate and had
recently implanted a double J stent (less than a week ago) or programmed for it, with an expected indwelling time below 8 weeks. Exclusion criteria comprised patients with programmed stent removal prior to 3 weeks from the inclusion visit, pathologies incompatible with the consumption of the oral composition, and uric or cystinuric patients in which different pH control recommendations are needed (Fig. 1). All patients finally enrolled were stone-formers with an indwelled double J stent for urine derivation due to endourological procedures.

Locations of data collection
The study was conducted in the following nine (9) public hospitals in Spain: 1) Hospital Universitari de Bellvitge, Barcelona 2) Hospital Clínico Universitario San Cecilio, Granada, 3) Hospital Universitario La Paz, Madrid, 4) Hospital Universitari i Politècnic La Fe, Valencia, 5) Complejo Hospitalario Universitario de Santiago de Compostela (CHUS), Santiago de Compostela 6) Hospital Universitario Rio Hortega, Valladolid, 7) Hospital Universitario de Valme, Sevilla, 8) Fundación Puigvert, Barcelona 9) Hospital Álvaro Cunqueiro, Vigo.

Treatment description
Subjects were randomly assigned in a 1:1 ratio to receive an oral composition (containing a urine acidifier and crystallization inhibitors) or placebo as investigators included them in a password-protected computer database with a pre-programmed randomization list with blocks of 2 to 4. The CRO (BioClever, Barcelona, Spain) generated the random allocation sequence, the hospitals enrolled the participants and the investigators assigned the participants to interventions. The oral composition arm consisted in oral administration of three capsules per day (1-1-1) to maintain the urine pH under 6.2, a preventive pH value, and increase the urine excretion of crystallization inhibitors to avoid stent encrustation(15,25). Patients in placebo arm received a treatment consisting in oral capsules with the same organoleptic and posology characteristics as the investigational compound. Both arms used a portable medical device (Lit-Control® pH Meter) to self-monitor their urinary pH every morning, and identical hygienic-dietary indications for stent care were given to all participants.

Follow-up evaluation
Intervention and pH self-control duration ranged from 3 to 8 weeks depending on the time-lapses between the baseline visit and the stent removal. Once removed, the process consisted in
submerging the stent ends in thymol to cleanse, gently letting them air dry over paper. This procedure prevents the growth of microorganisms and the crystallization progression to guarantee the correct encrustation evaluation. All analyses were carried out in a central laboratory (Laboratory of Investigation in Renal Lithiasis, Universidad de las Islas Baleares-IUNICS). Stents ends were cut and processed to examine the renal and vesical ends separately, in a homogenous fashion among the distinct enrolled centres according to protocol instructions.

**Outcome measures**

Primary outcome: The presence and degree of stent encrustation. A 4-level score was employed to determine the degree of encrustation, which area was quantified in squared millimetres (mm\(^2\)) (0: without inlay; 1: sporadic calcifications, less than 1–2 mm\(^2\); 2: calcification of wide areas, greater than 1–2 mm\(^2\); 3: global encrustation (= complete block) (Fig. 2). The 0 score was divided in 2 categories: with or without the presence of conditioning film; this division does not affect the final value of encrustation. An exponential transformation of the score was additionally applied, because calcium concentration ratios, measured by Arsenazo III spectrophotometry, were following log scale. A dichotomous variable for global encrustation (score 3) was created and used in the stent ends database. The type and size of crystals were assessed by SEM and micro-analysis by dispersive energy of X-Ray, and the degree of global encrustation of each end was measured using ICP-AES spectroscopy (Fig. 2). The type of deposit, presence of bacteria, and the size and nature of the crystals were identified using scanning electron microscopy (Hitachi S 3400 N), coupled to a microanalysis by X-Ray dispersive energy (Bruker AXS GmbH, Karlsruhe, Germany).

Secondary outcomes: Urinary pH reduction together with duration and method of the stent extraction intervention were recorded as secondary outcomes. First morning void as a spot urine sample, was performed daily. Specifically for the quantification of urinary pH change during the study period, the following was registered: i) an hospital measure of urine pH was considered as day 0; ii) mean domiciliary values of urine pH from days 1–3 were considered the baseline of pH self-monitoring data; iii) pH domiciliary values at day 21 and iv) mean domiciliary pH values from day 4 to the end of indwelling period (21 to 56 days). The baseline was compared to pH at day 21 and to the mean pH
values for the total indwelling period. Duration and method of the stent extraction intervention data were also recorded as secondary outcomes. Risk factors for encrustation development (days with implanted stent and number of previous implantations), stent-related symptoms, previous uropathies and sociodemographic data were also recorded to be studied as factors or covariates. Compliance was measured by counting returned medication, and consumption of more than 80% of the capsules was considered good adherence.

**Statistical analysis**

A sample size of 47 evaluable patients per treatment group would provide approximately 80% power to detect a reduction with an effect size of 0.6 in the encrustation score in either intervention group versus placebo using a Mann-Whitney U test. The sample was increased to 105 participants considering a 10% of dropouts. Demographic and baseline characteristics and safety and tolerability data were summarised using descriptive statistics. The primary endpoint, the difference in the encrustation score between groups, was assessed using a Fisher exact test for the categorical variable global encrustation and a Mann-Whitney U test for the encrustation scores, which were also analysed using Generalized Linear Models for a Tweedie distribution with a logarithmic link, including treatment, sex, baseline pH < 6 and indwelling duration > 39 days as fixed factors and age as a covariate. Mean differences and 95% confidence limits were calculated for all comparisons between groups. Global encrustation was analysed using a logistic regression model that included treatment, sex, baseline pH < 6, first implantation, indwelling duration and age. Secondary end points as pH reduction, intervention time for stent removal or patient satisfaction were analyzed using one-way analysis of variance. Statistics for all tables, figures, and graphs were calculated from the total number of valid cases. All statistical analyses were performed on the intention-to-treat population using SPSS 22.0 software for Windows.

**Results**

A total of 105 patients with a mean (SD) age of 51.6 (13.1) years were analysed (Fig. 1 and Table 1), with 198 stent ends collected from 99 subjects who wore them for an average time of 37.54 ± 13.9 days. Placebo and intervention group were comparable at baseline (see detailed parameters at
Concerning the presence or not of global encrustation as primary outcome, eight stent ends (8.2%) showed global encrustation in the placebo group and 1 (1.0%) in the intervention group (R.R.: 8.2 [1.04–64.06]; p = 0.018) in a period of 3–8 weeks, obtaining the same results than other authors in three previous studies(26–29). The encrustation degree scores by stent end are detailed in Table 2; the analysis of all the double J stent ends resulted in encrustation levels of 85.12 (274.5) in the placebo group, and of 18.91 (102.27) in the intervention group (p = 0.025); difference (95% IC) is 66.21 (8.37, 124.06). These results demonstrate an 8-fold reduction in global encrustation for the experimental group, together with a striking reduction in the degree of such encrustation in every analysis; when considering distinct stent ends or the sum of all ends.

### Table 1
**Characteristics of the study population**

|                      | Placebo group | Nutraceutical group | Total | p-value |
|----------------------|---------------|---------------------|-------|---------|
| N (%)                |               |                     |       |         |
| Sex                  |               |                     |       |         |
| Male                 | 28 (53.8)     | 30 (56.6)           | 58 (55.2) | 0.85    |
| Female               | 24 (46.2)     | 23 (43.4)           | 47 (44.8) |         |
| Total                | 52 (100)      | 53 (100)            | 105 (100) |         |
| Age                  |               |                     |       | 0.95    |
| Mean (SD)            | 51.5 (13.2)   | 51.7 (13.0)         | 51.6 (13.1) |         |
| Age                  |               |                     |       | 0.95    |
| Previous obstructive uropathy | 19 (36.5) | 21 (39.6) | 40 (38.1) | 0.84    |
| Previous stenting    | 19 (36.5)     | 22 (41.5)           | 41 (39)  | 0.69    |
| Urolithiasis as cause of current implantation | 41 (78.8) | 41 (77.4) | 82 (78.1) | 0.85    |
| Type of calculi      |               |                     |       | 0.80    |
| Calcium oxalate      | 19 (46.3)     | 21 (51.2)           | 40 (48.8) |         |
| Others               | 22 (53.7)     | 20 (48.7)           | 42 (51.2) |         |
| Total                | 41 (100)      | 41 (100)            | 82 (100)  |         |
| Stent material       |               |                     |       | 0.45    |
| Polyurethane         | 23 (44.3)     | 20 (37.7)           | 43 (40.9) |         |
| Silicone             | 1 (1.9)       | 0 (0)               | 1 (1)   |         |
| Percuflex            | 28 (53.8)     | 33 (62.3)           | 61 (58.1) |         |
| Implantation period (days) | 39.7 (14.9) | 35.4 (12.7) | 37.54 (13.9) | 0.12|
| Basal urinary pH     | 43 (100)      | 44 (100)            | 87 (100)  | 0.62    |
| Mean (SD)            | 6.2 (0.6)     | 6.3 (0.8)           | 6.3 (0.7)  |         |
| SD                   |               |                     |       |         |

SD = standard deviation.
Group homogeneity at baseline.

### Table 2
**Between groups analysis**

|                      | Placebo | Nutraceutical | Inference |
|----------------------|---------|---------------|-----------|
|                      | Mean (SD) | n | Mean (SD) | n | Difference/OR (95% CI) | p |
| Encrustation         |          |    |          |    |                        |   |
| Kidney stent end     | 64.73 (241.74) | 49 | 7.66 (23.69) | 50 | 57.07 (-11.1, 125.25) | 0.89 |
| Bladder stent end    | 105.51 (304.99) | 49 | 30.16 (142.52) | 50 | 75.35 (-19.3, 170.00) | 0.65 |
| Sum of stent ends    | 170.24 (513.58) | 49 | 37.82 (159.24) | 50 | 75.35 (-19.28, 169.99) | 0.65 |
| Maximum of stent ends| 105.69 (304.93) | 49 | 30.34 (142.49) | 50 | 132.43 (-18.62, 283.47) | 0.67 |

Encrustation adjusted for baseline using all
Encrustation adjusted for baseline urine pH

| Stent Type | Mean (SD)      | N (%) | Mean (SD)      | n (%) | Difference/OR (95% CI) | p     |
|------------|----------------|-------|----------------|-------|------------------------|-------|
| Kidney stent end | 48.31 (127.15) | 39    | 6.7 (24.51)   | 37    | 41.61 (2.77, 80.45)   | 0.036 |
| Bladder stent end | 77.68 (157.81) | 39    | 10.77 (33.03) | 37    | 66.91 (19.17, 114.65) | 0.006 |
| Sum of stent ends | 78.34 (158.44) | 39    | 11.11 (32.97) | 37    | 67.23 (19.18, 115.29) | 0.006 |
| Maximum of stent ends | 125.99 (268.1) | 39    | 17.47 (53.53) | 37    | 108.52 (26.83, 190.21) | 0.009 |

Encrustation adjusted for baseline urine pH, age, gender and indwelling duration

| Stent Type | Mean (SD)      | N (%) | Mean (SD)      | n (%) | Difference/OR (95% CI) | p     |
|------------|----------------|-------|----------------|-------|------------------------|-------|
| Kidney stent end | 11.75 (21.42) | 39    | 4.47 (9.91)   | 37    | 7.28 (-0.57, 15.14)   | 0.07  |
| Bladder stent end | 56.53 (121.15.5) | 39    | 17.87 (48.30) | 37    | 38.66 (1.69, 75.62)   | 0.04  |
| Sum of stent ends | 57.57 (122.09) | 39    | 18.27 (48.42) | 37    | 39.0 (2.02, 76.57)    | 0.039 |
| Maximum of stent ends | 79.79 (168.24) | 39    | 26.5 (681.92) | 37    | 53.30 (1.74, 104.85)  | 0.039 |

Urine pH

| Measured Parameter | Mean (SD) | N (%) | Mean (SD) | n (%) | Difference/OR (95% CI) | p     |
|--------------------|-----------|-------|-----------|-------|------------------------|-------|
| pH reduction baseline (24 h) to day 21 | 0.39 (0.7) | 28    | 0.86 (0.78) | 32    | -0.47 (-0.85, -0.084)  | 0.018 |
| pH reduction day 1 to day 21 | 0.37 (0.55) | 35    | 0.65 (0.58) | 35    | -0.28 (-0.55, -0.006)  | 0.045 |
| pH reduction days 1-3 to day 21 | 0.17 (0.49) | 36    | 0.54 (0.58) | 36    | -0.37 (-0.62, -0.11)   | 0.005 |
| Difference between pH mean of days with stent and pH mean of days 1-3 | -0.2 (0.32) | 40    | -0.48 (0.44) | 39    | 0.28 (0.11, 0.45)      | 0.002 |
| pH slope | -.0061 (.013) | 40    | -.014 (0.02) | 39    | 0.008 (0.00006, 0.016)  | 0.042 |

Stent removal

| Measured Parameter | Mean (SD) | N (%) | Mean (SD) | n (%) | Difference/OR (95% CI) | p     |
|--------------------|-----------|-------|-----------|-------|------------------------|-------|
| Removal surgery time (min) | 13.8 (30.5) | 52    | 7.23 (13.5) | 52    | 2.66 [0.49-14.37]      | 0.44  |
| Removal surgery time (adjusted, min) | 40.9 (5.8) | 52    | 9.5 (4.15) | 52    | < 0.001                |       |
| Stent removed at first attempt | 47 | 48.5 | 50 | 51.5 | 2.66 [0.49-14.37] | 0.44 |

Patient’s satisfaction

| Measured Parameter | Mean (SD) | N (%) | Mean (SD) | n (%) | Difference/OR (95% CI) | p     |
|--------------------|-----------|-------|-----------|-------|------------------------|-------|
| With nutraceutical | 7.5 (2.6) | 52    | 7.6 (2.2) | 52    | 0.74                   |       |
| With pH meter | 7.6 (2.2) | 52    | 8.4 (1.9) | 52    | 0.39                   |       |

As for secondary outcome, the reduction in urinary pH from the baseline or day 1 to values obtained after all the indwelling period was significantly greater in the intervention group (Table 2). These data show that the administration of the new oral composition is effective in decreasing the urinary pH as a preventive measure for stent calcifications.

Binary logistic regression model of all stent ends global encrustation showed a OR in the placebo
group of 20.61 [95% IC: 1.66 - 256.2; p = 0.019] emerging as protective factors age > 47, first implantation and baseline pH < 6 and favoring encrustation would be male gender (Fig. 3). Four (22%) of 18 patients whose mean pH level during indwelling was greater than 6 showed global encrustation in 7 stent ends and 1 (1.7%) of 58 patients with lower pH levels showed this outcome in 1 stent end (RR: 12.9 [1.4-296.7]; p < 0.012).

Spearman correlation between indwelling time in days and encrustation score was $\rho = 0.212$ ($p < 0.036$) for the kidney end and $\rho = 0.153$ ($p < 0.13$) for the bladder end. When separated by study group, $r^2$ of encrustation score at kidney end by indwelling time was 0.079 for the placebo group and 0.018 for the nutraceutical group.

The total amount of calcium deposited in stents with encrustation scores of 3 was thousand times greater than the amount in stents with score 1 (Table 3), justifying an exponential transformation of the score. Tables 4 and 5 summarize the types of scale and the magnitude of the deposits; in the 28.3% of the stents no deposit was observed in the bladder part, while in the renal part there were no deposits in 41.4%.

| Magnitude of the scale | Id   | Calcium deposit  |
|------------------------|------|-----------------|
| Type 1                 |      |                 |
| 49 bladder             | 0.95 nmol / cm |
| 59 bladder             | 1.21 nmol / cm |
| 43 renal               | 0.84 nmol / cm |
| 49 renal               | 0.42 nmol / cm |
| 50 renal               | 0.85 nmol / cm |
| Type 3                 |      |                 |
| 41 bladder             | 330 nmol / cm |
| 3 bladder              | 346 nmol / cm |
| 72 bladder             | 244 nmol / cm |
| 3 renal                | 329 nmol / cm |
Table 4
Scale types observed on the stent. Bladder end (location). (N = 99)

| Type of scale                          | Magnitude of the scale |
|----------------------------------------|------------------------|
|                                        | 0  | 1   | 2   | 3  |
| No deposit                             | 28 | (28.3%) |     |    |
| Organic matter                         | 12 | (12.1%) |     |    |
| Calcium oxalate monohydrate            |    |        | 24  | (24.2%) |
| Calcium oxalate monohydrate + calcium oxalate dihydrate |    |        | 14  | (14.1%) |
| Brushite                               | 2  | (2.0%)  | 1   | (1.0%) |
| Hydroxyapatite                         | 1  | (1.0%)  | 1   | (1.1%) |
| Hydroxyapatite + brushite              | 1  | (1.0%)  | 3   | (3.0%) |
| Uric acid                              |    |        | 3   | (3.0%) |
| Uric acid + calcium oxalate monohydrate| 1  | (1.0%)  |     |    |
| Bacteria                               | 4  | (4.0%)  |     |    |
| Hydroxyapatite + ammonium magnesium phosphate |    |        | 2   | (2.0%) |
| Brushite + calcium oxalate dihydrate   | 1  | (1.0%)  |     |    |
| Ammonium urate                         | 1  | (1.0%)  |     |    |

Table 5
Scale types observed on the stent. Renal end (location). (N = 99)

| Type of scale                          | Magnitude of the scale |
|----------------------------------------|------------------------|
|                                        | 0  | 1   | 2   | 3  |
| No deposit                             | 41 | (41.4%) |     |    |
| Organic matter                         | 8  | (8.1%)  |     |    |
| Calcium oxalate monohydrate            |    |        | 27  | (27.3%) |
| Calcium oxalate monohydrate + calcium oxalate dihydrate |    |        | 11  | (11.1%) |
| Brushite                               | 2  | (2.0%)  |     |    |
| Hydroxyapatite                         | 1  | (1.0%)  |     |    |
| Hydroxyapatite + brushite              |    |        | 3   | (3.0%) |
| Uric acid                              |    |        | 2   | (2.0%) |
| Uric acid + calcium oxalate monohydrate| 1  | (1.0%)  |     |    |
| Bacteria                               | 2  | (2.0%)  |     |    |
| Hydroxyapatite + ammonium magnesium phosphate |    |        | 1   | (1.0%) |

The deposits consist mainly of organic matter only (12.1% bladder part – 8.1% renal part) or small crystals of calcium oxalate monohydrate (COM or COM + COD) developed on top of a layer of organic matter. In addition, bacteria were on the surface of the bladder part in 4.0% of the stents and on the renal part in 2.0% of the stents. In all cases, bacteria were on top of the layer of initially deposited organic matter (Fig. 4).
The non-continuous deposits of thickness greater than 1 to 2 mm, mainly consisted of hydroxyapatite (1.1% in the bladder part), hydroxyapatite + ammonium magnesium phosphate (1.0% in the renal part) and uric acid (3.0% in the bladder and 2.0% in the renal part, Fig. 5). Larger depositions, which can cause obstructions and/or complete block, were mainly brushite and hydroxyapatite (3.0% in the renal part and 4.0% in the bladder part, shown in Fig. 5), and magnesium ammonium phosphate (2.0% in the bladder part, Fig. 6). Although the deposits of magnesium ammonium phosphate are clearly of bacterial colonization origin, no bacteria were detected in the crystals.

Fifteen patients (37.5%) in the placebo group and 12 (30%) in the intervention group took less than 80% of prescribed doses (p = 0.6). Twelve patients (11.4%) in the placebo group and 14 (13.3%) in the intervention group failed to provide valid pH measures due to inadequate use of the device. Three patients in the placebo group reported mild adverse events (2 nausea and 1 hot flashes) and 3 in the intervention group (1 diarrhea, 1 blurry vision and 1 dyspepsia). Two patients in the placebo group discontinued the study due to adverse events. No additional measures needed to be taken for the rest of the patients due to adverse effects. Six patients in the placebo group and 6 patients in the intervention group were prescribed with antibiotics due to positive baseline urine cultures.

Discussion

The calcification phenomenon has relevant clinical consequences that may compromise stent removal. When indwelling time increases, encrustation prevalence increases proportionally(26) and global encrustation can occur, leading to the use of endourological techniques, extracorporeal lithotripsy or open surgery to resolve these conditions(8,30). Although heavily encrusted stents clearly do pose significant problems, minor encrustations can also challenge the endourologist, particularly if occurring frequently and repetitively(27). Some publications indicate that the mere presence of a biofilm in the stent increase patient’s discomfort and lower urinary tract symptoms (LUTS)(11,31), which may increase inflammation, tissue damage and eventually affect stent removal.

To this date, no oral treatment to prevent or decrease stent encrustation have been proposed.

The degree of stent encrustation was strikingly reduced in the experimental group treated with the oral composition, when considering each stent end separated or their sum, as well when adjusting the
data for baseline urine pH, age, sex, previous implantation and indwelling duration. Particularly for those stents with a global encrustation value, the difference between the intervention group and placebo yielded a relative risk of 8.2 and this effect was enhanced by baseline pH level. The microscopic study of the stents indicated that organic matter in the urine (macromolecules or cellular debris) is first deposited on the stent forming a layer (conditioning film) that is several micrometers thick (Fig. 2, encrustation definition 0(f)). The thickness and composition of the conditioning film depend on the urine composition of the patient. For patients with non-lithogenic urine (no hypercalciuria, no hyperoxaluria, no hypocitraturia, and a urinary pH between 5.5 and 6.2) and no bacterial colonization of the urine, organic matter deposits can occur, and act as heterogeneous nucleants that support the growth of COM crystals over 2 to 3 months (32,33). This growth is very slow, forming only a thin layer (thickness of several micrometers) (Fig. 2). The underlying mechanism may be analogous to the formation of COM stones in renal cavities (32). If a patient has a high level of urinary calcium, then COD crystals may develop. If bacteria are present, they can colonize the stent surface and grow while embedded in the initially deposited organic matrix (Fig. 4). The biofilm resulting from infection by urease-producing bacteria increases the urinary pH and leads to the formation of carboxyapatite and magnesium ammonium phosphate crystals (Fig. 6). Depending on bacterial activity, these crystals can range from small deposits to large concretions, and, in many cases, they obstruct the inflow and outflow through the stent, and make the stent extraction much more difficult for the urologist. The most common bacteria in these deposits is P. mirabilis (34,35). It is interesting to observe how the presence of bacteria on the organic matter layer has been detected, forming the biofilm, but they have not been identified on the magnesium ammonium phosphate crystals, which are clearly infectious. This can be explained considering that the bacteria are installed in the areas between the organic matter and the surface of the crystalline deposit, thus being also protected from the action of antibiotics. For urine with a pH higher than 6.2 and no bacterial colonization, significant deposits of calcium phosphate can develop depending on the specific conditions. In particular, when the urine has a high calcium concentration, a citrate deficit, and a pH greater than 6.2, large deposits of brushite can build
(Fig. 6) (32,33). Under these conditions, large COD crystals can also occur. When the calcium and magnesium concentrations are low, large hydroxyapatite deposits can develop. For urine with a pH less than 5.5, major deposits of uric acid can develop (Fig. 5). It is important to point out that, in urinary pH values between 5.5 and 6.2, the crystalline development occurs at such a rate that does not allow the development of large deposits and consequent obstructions.

The multivariate models showed that the formation of deposits in the double J stent ends is a multifactorial process dependent on patient’s previous implantation, duration of the implantation period, baseline pH level, and the use of an oral composition (Fig. 3). Both oral composition and baseline pH are independent factors that prevent stent encrustation. A mean pH greater than 6.2 during indwelling time increased 12.9 times the risk of global encrustation of a stent end. In addition, the experimental group has a higher urinary pH decrease from baseline to the end of the indwelling period. The fact that the oral composition studied consists in an acidifier (L-methionine) plus an inhibitor (phytin) may account for it, since both components have a synergic effect on reducing urine pH and inhibiting urine crystallization, respectively, which may prevent encrustation (12,18,19).

A better adherence to treatment could add more value to the final data; 37.5% of patients in the placebo group and 30% in the experimental took less than 80% of prescribed doses. Additionally, both intervention and placebo groups lowered their urine pH levels; this may be since hygienic-dietary indications for stent care were given to all participants and to the daily urine pH self-monitoring carried out by both groups. Patients scored their satisfaction with the pH meter with an average of 8 over a 0 to 10 scale.

This study has some limitations. It would be useful if metabolic urine studies were performed prior and after the administration of the oral composition and/or the placebo. However, most of the cases included in our trial came from the emergency room (ER) or from peri-surgical situations, making difficult to collect urine samples for metabolic analysis. In addition, it was considered a possibility of bias in the urinary metabolic parameters due to such hospitalization and surgical interventions. It is a pioneer study, consisting in the first controlled, prospective, randomized and multicenter trial collecting and analyzing 198 stent ends, and for this first assumption of the potential benefits of the
proposed therapy, one could consider up to 56 days a short indwelling time. It asks for next steps, which will be a study comprising longer periods to validate the treatment.

To our knowledge this is the first report of a potential oral treatment to prevent double J ureteral stent encrustation by changing the urine composition of the patients.

Conclusion
The use of an oral composition in patients indwelling a double J ureteral stent resulted in fewer stent encrustations.

Abbreviations
GCP:Good clinical practice; COM:calcium oxalate monohydrate; COD:calcium oxalate dihydrate;
ER:emergency room

Declarations

Ethics approval and consent to participate
The study was approved by the Ethical and Clinical Investigation Committee from the Bellvitge University Hospital (internal reference number AC009/17). Written informed consent was obtained from all patients prior to their enrolment in the study.

Consent for publication
Written informed consent was obtained from all patients for publication of this study.

Availability of data and materials
The data analysed during the current study are available from the corresponding author on reasonable request.

Competing interests
Jordi Cuñé certifies that all conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript are the following: Jordi Cuñé is a full-time employee at Devicare S.L.

The other authors have nothing to disclose.

Funding
Devicare SL acted as sponsor of the study, providing the placebo and experimental products, the pH meter and a fee corresponding to 80 euros/patient enrolled to medical doctors. The costs concerning
the standard medical management of each patient during the study was conventionally assumed by the enrolled hospitals.

**Authors’ contributions**

CT and JFC contributed to the conception, design, acquisition and interpretation of data, drafted and revised the work. JRC, JAM, JHA, SC, OA, EE, MAM, MAP, AG, MCR, JFA, AB, DP contributed to the acquisition and interpretation of data, drafted and revised the work. FG and ACB contributed to the interpretation and analysis of data, drafted and revised the work, JC contributed to the conception, design, drafted and revised the work. All authors have approved the submitted version. All authors have agreed both to be personally accountable for the author’s own contributions and to ensure that questions related to the accuracy or integrity of any part of the work.

**Acknowledgements**

The authors thank the patients, their families and the physicians involved.

**Authors’ details**

1 Bellvitge University Hospital, Barcelona. 2 La Paz University Hospital, Madrid. 3 Rio Hortega Hospital, Valladolid. 4 Mateu Orfila Hospital, Mahón, Balearic Islands. 5 Puigvert Foundation, Barcelona. 6 San Cecilio University Hospital, Granada. 7 Valme University Hospital, Sevilla. 8 Álvaro Cunqueiro Hospital, Vigo. 9 La Fe University Hospital and Polytechnic, Valencia. 10 University Hospital of Santiago of Compostela, Santiago of Compostela. 11 Laboratory of Renal Lithiasis Research, University Institute of Health Sciences Research (IUNICS- IDISBA), University of Balearic Islands. 12 Devicare SL, (Barcelona)

**References**

1. Finney RP. Experience with new double J ureteral catheter stent. J Urol. 1978;120(6):678-81.
2. González-Ramírez M, Méndez-Probst C, Feria-Bernal G. Factores de riesgo y manejo en la calcificación del catéter doble J. Rev Mex Urol. 2009;69(0155):7-12.
3. Saltzman B. Ureteral stents. Indications, variations, and complications. Uro Clin North
4. Stickler DJ. Clinical complications of urinary catheters caused by crystalline biofilms: Something needs to be done. J Intern Med. 2014;276(2):120-9.

5. Beysens M, Tailly TO. Ureteral stents in urolithiasis. Asian J Urol [Internet]. 2018;5(4):274-86. Available from: https://doi.org/10.1016/j.ajur.2018.07.002

6. Türk C, Neisius A, Petrik A, Seitz C, Skolarikos A, Thomas K. EAU Guidelines on Urolithiasis. Eur Assoc Urol [Internet]. 2018;69(3):475-82. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26344917%5Cnhttp://uroweb.org/wp-content/uploads/22-Urolithiasis_LR_full.pdf

7. Acosta-Miranda AM, Milner J, Turk TMT. The FECal Double-J: A Simplified Approach in the Management of Encrusted and Retained Ureteral Stents. J Endourol. 2009;23(3):409-15.

8. Angel M, Polo A, Nogueras M. CALCIFICACIÓN GIGANTE EN EXTREMO DISTAL DE STENT URETERAL. Arch Esp Urol. 2010;873-6.

9. Sighinolfi MC, Sighinolfi GP, Galli E, Micali S, Ferrari N, Mofferdin A, et al. Chemical and Mineralogical Analysis of Ureteral Stent Encrustation and Associated Risk Factors. Urology. 2015;86(4):703-6.

10. Burr RG, Nuseibeh IM. Urinary catheter blockage depends on urine pH, calcium and rate of flow. Spinal Cord. 1997;35(8):521-5.

11. Zumstein V, Betschart P, Albrich W, Buhmann M, Ren Q, Schmid H, et al. Biofilm formation on ureteral stents - Incidence, clinical impact, and prevention. Swiss Med Wkly. 2017;3 February:1-10.

12. Mosayyebi A, Manes C, Carugo D, Somani BK. Advances in Ureteral Stent Design and Materials. Curr Urol Rep. 2018;19(5).

13. HEDELIN H, BRATT C -G, ECKERDAL G, LINCOLN K. Relationship between Urease-
producing Bacteria, Urinary pH and Encrustation on Indwelling Urinary Catheters. Br J Urol. 1991;67(5):527-31.

14. Kohler-Ockmore J, Feneley R. Long-term catheterization of the bladder: prevalence and morbidity. Br J Urol. 1996;77(3):347-51.

15. Siener R, Struve F, Hesse A. Effect of L-methionine on the risk of phosphate stone formation Corresponding author: Phone: phosphate, urinary stones. Urology [Internet]. 2016; Available from: http://dx.doi.org/10.1016/j.urology.2016.08.007

16. Passaro M, Mainini G, Ambrosio F, Sgambato R BG. Effect of a Food Supplement Containing L-Methionine on Urinary Tract Infections in Pregnancy: A Prospective, Multicenter Observational Study. J Altern Complement Med. 2017;00(00):1-8.

17. Grases F, Isern B, Sanchis P, Perello J, Torres JJ C-BA. Phytate acts as an inhibitor in formation of renal calculi. Front Biosci. 2007;12(1):2580.

18. del Valle EE, Spivacow FR N AL. CITRATO Y LITIASIS RENAL Metabolismo renal del citrato. Med (Buenos Aires). 2013;73:363-8.

19. Gul Z, Monga M. Medical and dietary therapy for kidney stone prevention. Korean J Urol. 2014;55(12):775-9.

20. Grases F, Rodriguez A, Berga F, Costa-Bauza A, Prieto RM, Burdallo I, et al. A new device for simple and accurate urinary pH testing by the Stone-former patient. Springerplus. 2014;3(1):1-5.

21. De Coninck V, Keller EX, Rodríguez-Monsalve M, Doizi S, Audouin M, Haymann J-P, et al. Evaluation of a Portable Urinary pH Meter and Reagent Strips. J Endourol. 2018;32(7):647-52.

22. Yang L, Wang K, Li H, Denstedt J, Cadieux P. The influence of urinary pH on antibiotic efficacy against bacterial uropathogens. J Urol. 2014;84(3):731e1-731e7.

23. Nakanishi N, Fukui M, Tanaka M, Toda H, Imai S, Yamazaki M, et al. Low urine pH is a
predictor of chronic kidney disease. Kidney Blood Press Res. 2012;35(2):77-81.

24. Carlsson S, Wiklund NP, Engstrand L, Weitzberg E, Lundberg JON. Effects of pH, nitrite, and ascorbic acid on nonenzymatic nitric oxide generation and bacterial growth in urine. Nitric Oxide - Biol Chem. 2001;5(6):580-6.

25. Hesse A, Heimbach D. Causes of phosphate stone formation and the importance of metaphylaxis by urinary acidification: A review. World J Urol. 1999;17(5):308-15.

26. el-Faqih SR, Shamsuddin AB, Chakrabarti A, Atassi R, Kardar AH OM, I H. Polyurethane internal ureteral stents in treatment of stone patients: morbidity related to indwelling times. J Urol. 1991;1487-91.

27. Bultitude MF, Tiptaft RC, Glass JM, Dasgupta P. Management of encrusted ureteral stents impacted in upper tract. Urology. 2003;62(4):622-6.

28. Kamberi M, Tsutsumi K, Kotegawa T, Kawano K, Nakamura K, Niki Y, et al. Influences of urinary pH on ciprofloxacin pharmacokinetics in humans and antimicrobial activity in vitro versus those of sparfloxacin. Antimicrob Agents Chemother. 1999;43(3):525-9.

29. Kawahara T, Ito H, Terao H, Yoshida M, Matsuzaki J. Ureteral Stent Encrustation, Incrustation, and Coloring: Morbidity Related to Indwelling Times. J Endourol. 2012;27(4):506-506.

30. Perez-Fentes D. Complications of double j catheters and their endourological management. Arch Esp Urol. 2016;69(8):527-43.

31. Bonkat G, Rieken M, Müller G, Roosen A, Siegel FP, Frei R, et al. Microbial colonization and ureteral stent-associated storage lower urinary tract symptoms: The forgotten piece of the puzzle? World J Urol. 2013;31(3):541-6.

32. Grases F, Söhnel O, Costa-Bauzá A, Ramis M, Wang Z. Study on concretions developed around urinary catheters and mechanisms of renal calculi development.
Nephron. 2001;88(4):320–8.

33. Grases F, Costa-Bauzá A, Ramis M, Montesinos V, Conte A. Simple classification of renal calculi closely related to their micromorphology and etiology. Clin Chim Acta. 2002;322(1–2):29–36.

34. Cox AJ, Hukins DWL. Morphology of mineral deposits on encrusted urinary catheters investigated by scanning electron microscopy. J Urol [Internet]. 1989;142(5):1347–50. Available from: http://dx.doi.org/10.1016/S0022-5347(17)39095-X

35. Stickler DJ. Bacterial biofilms in patients with indwelling urinary catheters. Nat Clin Pract Urol. 2008;5(11):598–608.

Figures
Figure 1

Patient flow chart and allocation.
Encrustation measurement of Double J ureteral stent

| Radiographic image |
|--------------------|
| ![Radiographic images](image1) |

| Macroscopic view |
|------------------|
| ![Macroscopic images](image2) |

| Electron microscope |
|---------------------|
| ![Electron microscope images](image3) |

| Definition | without Inlay | sporadic calcifications | calcifications of wide areas | complete blockage |
|------------|---------------|--------------------------|-----------------------------|------------------|
| Exp. Score (10^3) | 0 | 0 (f) | < 1-2mm² | > 1-2mm² | complete blockage |
| 0 | 1 | 10 | 100 | 1000 |

(f) presence of film

Figure 2

Encrustation measurement from 0 (nothing) to 4 (global encrustation) measured by radiographic image, microscopic view and electron microscope of the stent.
Logistic Regression Model - Dependent Variable: Global Encrustation

| Factor                     | OR  | 95%CI   | p-value |
|----------------------------|-----|---------|---------|
| Nutraceutical              | 0.05| 0.004 - 0.6 | 0.019  |
| Age >47 Yr (1st tercile)  | 18.9| 2.17 - 164.83 | 0.008  |
| Female Gender              | 0.05| 0.005 - 0.53 | 0.012  |
| First catheterization      | 0.04| 0.003 - 0.48 | 0.011  |
| Indwelling period (days)   | 1.11| 1.02 - 1.2  | 0.011  |
| Baseline pH                | 8.75| 1.4 - 54.73 | 0.02   |

Logistic Regression Model of dependent variables for global encrustation. OR = Odds Ratio; CI = confidence interval. Dependent factors: nutraceutical group, age over 47 years, female gender, first catheterization, indwelling period in days, baseline pH level.

Figure 3

Multivariate model of Double J ureteral stent encrustation
Figure 4

Surface of a stent covered by an organic matter layer (conditioning film) in which colonies of bacteria have developed (encrustation classified as 1).
Figure 5

Surface of a stent covered by dihydrate uric acid deposits, classified as 2. (A) Optical image, (B) Scanning electron microscopy image.
Figure 6

Surface of a stent covered by ammonium magnesium phosphate + hydroxyapatite deposits
(A) Optical image, (B) Scanning electron microscopy image. Surface of a stent covered by brushite + hydroxyapatite deposits (C) Optical image, (B) Scanning electron microscopy image.

Supplementary Files
This is a list of supplementary files associated with this preprint. Click to download.
CONSORT 2010 Checklist filled out Torrecilla et al.doc